DENVER, Feb. 25 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disorders, today announced that J. William Freytag, President
and Chief Executive Officer, will present a corporate overview at the Leerink
Swann Inaugural Health Care Conference.
The presentation will take place at 1:00 p.m. (Eastern) on Tuesday,
March 1, 2005. There will be a live webcast of the presentation, which will
be accessible through a link posted on the investor relations section of the
Myogen website at http://investor.myogen.com/. The webcast will be available
for replay on Myogen's website through March 18, 2005.
Myogen currently markets one product (Perfan(R) I.V.) in Europe for the
treatment of acute decompensated heart failure and has three product
candidates in late-stage clinical development: enoximone capsules for the
treatment of advanced chronic heart failure, ambrisentan for the treatment of
pulmonary arterial hypertension and darusentan for the treatment of resistant
hypertension. The company, in collaboration with Novartis, also conducts a
target and drug discovery research program focused on the development of
disease-modifying drugs for the treatment of chronic heart failure and related
cardiovascular disorders. Please visit our website at http://www.myogen.com.
Safe Harbor Statement
The anticipated presentation will contain forward-looking statements that
involve significant risks and uncertainties, including those to be discussed
in the presentation and others that can be found in the "Risk Factors" section
of Myogen's Form 10-K for the year ended December 31, 2003, Myogen's Form S-3
filed on October 29, 2004 and Myogen's periodic reports on Form 10-Q and Form
8-K. Myogen does not undertake any obligation to update any forward-looking
statements contained in the anticipated presentation as a result of new
information, future events or otherwise. The company cautions investors not
to place undue reliance on the forward-looking statements contained in this
press release or the presentation. No forward-looking statement can be
guaranteed and actual events and results may differ materially from those
projected.
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations
of Myogen, Inc., +1-303-464-3986, derek.cole@myogen.com
|
